&w=3840&q=100)
Why did Shilpa Medicare share jump 5% in trade today? top details here
Around 1:30 PM, Shilpa Medicare share price was trading 4.93 per cent higher at ₹938.50. By comparison, BSE Sensex was trading 0.08 per cent lower at 82,640.01 levels. CATCH STOCK MARKET LIVE UPDATES TODAY
Why did Shilpa Medicare share price rise in trade today?
Shilpa Medicare share price gained in trade after the company announced a positive regulatory update from the US health regulator, United States Food and Drug Administration (USFDA).
The pharma firm said its Unit VI at Dabaspet, Bengaluru received an Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA. The EIR followed a Good Manufacturing Practices (GMP) inspection conducted between October 24-30, 2024.
In an exchange filing, Shilpa Medicare said, 'This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspet, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 – 30, 2024.'
The unit is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms including Oral Dissolving Films and Transdermal Systems.
Meanwhile, the unit already holds approvals from key global regulators, including EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia). It currently supplies oral film products to the US and other markets, while filings for transdermal products have been made in Europe.
Shilpa Medicare Q4 results
Shilpa Medicare reported a mixed set of numbers in Q4FY25. While revenue from operations grew 13.3 per cent year-on-year (Y-o-Y) to ₹330.80 crore and earnings before interest, tax, depreciation and amortisation (Ebitda) rose 15 per cent to ₹84 crore, net profit (PAT) declined 40.8 per cent to ₹14.51 crore.
About Shilpa Medicare
Shilpa Medicare Limited is a global pharmaceutical company with a strong presence in regulated markets such as the USA, Europe, and Japan.
The company specialises in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations, with a particular focus on oncology.
Its product range includes tablets, capsules, injectables, and transdermal patches, all manufactured to meet international quality standards. Additionally, Shilpa Medicare provides end-to-end Contract Development and Manufacturing Organisation (CDMO) services, catering to a wide spectrum of pharmaceutical needs.
Beyond its core offerings, the company is actively investing in research and development, focusing on novel drug delivery systems and expanding into emerging therapy areas, including biotech products.
The market capitalisation of Shilpa Medicare is ₹9,177.68 crore, according to BSE. The company falls under the BSE SmallCap category.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
a day ago
- Business Standard
Q1 results today: HDFC, ICICI Bank, Reliance Power, 18 others on July 19
HDFC Bank, ICICI Bank, JK Cement, Reliance Power, Punjab & Sind Bank and Union Bank of India are scheduled to announce their earnings report for the first quarter (Q1) of the financial year 2025-26 (FY26). Among other companies expected to declare their Q1 results are Central Bank of India, AU Small Finance Bank, Yes Bank Ltd, High Energy Batteries India Ltd, India Cements Ltd, and RBL Bank Ltd. Q1 preview for HDFC Bank Analysts at Kotak Institutional Equities (KIE) project HDFC Bank's net interest income (NII) to rise 5.3 per cent year-on-year (Y-o-Y) to ₹31,408.4 crore in Q1FY26, citing loan growth trailing the industry average. On a sequential basis, this would mark a 2.1 per cent decline from ₹32,065.8 crore in the previous quarter. The bank is working to improve its loan-to-deposit ratio (LDR), which has now reached nearly 95 per cent. Analysts at Motilal Oswal Financial Services expect a steady quarter for HDFC Bank, projecting mid-to-high single-digit growth in both NII and net profit. According to their estimates, HDFC Bank could post an NII of ₹31,900 crore in the June quarter, up 6.9 per cent Y-o-Y from ₹29,837.1 crore in Q1FY25. With other income estimated at ₹12,160 crore, the bank's total revenue for Q1FY26 is expected to reach ₹44,060 crore. Markets end lower amid volatility on July 18 Indian equity benchmark indices ended sharply lower on July 18 after a volatile trading session, weighed down by losses in Axis Bank, Kotak Bank, and Bharti Airtel. Weak investor sentiment was further impacted by FII selling, global uncertainty over US Fed policy, and rising crude oil prices. The BSE Sensex declined 501.5 points, or 0.61 per cent, to close at 81,757.73, while the Nifty50 dropped 143 points, or 0.57 per cent, to settle at 24,968.4. In the broader market, the Nifty Midcap 100 slipped 0.7 per cent and the Nifty Smallcap 100 lost 0.82 per cent. Follow the latest market updates here: Market News List of firms releasing Q1 FY26 results on July 19 ATV Projects India Ltd AU Small Finance Bank Ltd Can Fin Homes Ltd Central Bank of India Continental Securities Ltd EPACK Durable Ltd Gowra Leasing & Finance Ltd HDFC Bank Ltd High Energy Batteries India Ltd ICICI Bank Ltd India Cements Ltd JK Cement Ltd Punjab & Sind Bank RBL Bank Ltd Rossari Biotech Ltd Reliance Power Ltd Seshasayee Paper and Boards Ltd Union Bank of India Vanta Bioscience Ltd Vintage Coffee And Beverages Ltd Yes Bank Ltd
Hans India
a day ago
- Hans India
Bank stocks, FII outflows drag markets lower
Mumbai: Benchmark Sensex tanked 501 points while Nifty closed below the 25,000 mark on Friday due to selling in banking shares after muted quarterly earnings and foreign fund outflows. Falling for the second straight day, the 30-share BSE Sensex declined by 501.51 points or 0.61 per cent to settle at 81,757.73. During the day, it shed 651.11 points or 0.79 per cent to hit a low of 81,608.13. The 50-share NSE Nifty dropped 143.05 points or 0.57 per cent to close at a month's low of 24,968.40. Analysts said investors turned cautious over banking stocks in response to Axis Bank's latest financial results, which fell short of market expectations. Among Sensex firms, Axis Bank tumbled the most by 5.24 per cent after it reported a 3 per cent dip in its June quarter consolidated net profit at Rs 6,243.72 crore, impacted by the implementation of changes in non-performing assets and loan upgrade policy. Devarsh Vakil, Head of Prime Research, HDFC Securities, said Axis Bank's latest financial results fell short of market expectations. 'Notably, Axis Bank's GDR tumbled 4.8 per cent to USD 64.30 on Thursday, following a deterioration in the bank's asset quality during the June quarter,' he said. Among blue-chip bank stocks, Axis Bank, HDFC Bank, Kotak Mahindra Bank and State Bank of India ended lower. Following the decline in bank stocks, the BSE Bankex ended 1.33 per cent lower at 62,741.65. Bharat Electronics, Bharti Airtel, HDFC Bank, Kotak Mahindra Bank, Titan and Eternal were also among the laggards from the Sensex pack. However, Bajaj Finance, Tata Steel, ICICI Bank, HCL Tech and Infosys were among the gainers. Foreign Institutional Investors (FIIs) offloaded equities worth Rs 3,694.31 crore on Thursday, according to exchange data. 'A broad-based sell-off was observed amidst a disappointing initial set of earnings from the finance and IT sectors.
The Hindu
2 days ago
- The Hindu
Dr. Reddy's formulations facility in AP gets 7 U.S. FDA observations
The U.S. Food and Drug Administration (U.S. FDA) has issued seven observations to Dr. Reddy's Laboratories after an inspection of the generic drugmaker's formulations manufacturing facility in Srikakulam, Andhra Pradesh. 'The U.S. FDA today completed a GMP and a pre-approval inspection (PAI) at our formulations manufacturing facility FTO 11 in Srikakulam, AP. The inspection was conducted from July 10-18. We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline,' Dr. Reddy's said in a filing on Friday.
